dulanermin + cetuximab + irinotecan

dulanermin + cetuximab + irinotecan is an investigational combination regimen of three agents used in oncology, specifically in the treatment of metastatic colorectal cancer (mCRC). - **Dulanermin** is a recombinant soluble human Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) that binds to pro-apoptotic death receptors (DR4, DR5), activating extrinsic apoptotic pathways in tumor cells[2]. - **Cetuximab** is a monoclonal antibody targeting the Epidermal growth factor receptor (EGFR), inhibiting its signaling and reducing tumor cell proliferation[3][4]. - **Irinotecan** is a topoisomerase I inhibitor that induces DNA damage and apoptosis, used as a cytotoxic chemotherapy in colorectal cancer[4]. This combination leverages dulanermin’s apoptotic activation, cetuximab’s anti-EGFR activity, and the cytotoxic effect of irinotecan. Dulanermin has been evaluated with irinotecan-based regimens in clinical trials for the treatment of previously treated mCRC[2]. No evidence indicates the existence of a commercial product or unique brand name for this triple regimen; it has been tested only in clinical studies.

Other names

Apo2 ligandApo-2 ligandApo 2 ligandTNF-related apoptosis-inducing ligandrecombinant soluble human Apo2L/TRAILCPT-11CPT11CPT 11